Clinical Cancer Research

Last updated

History

The first issue of Clinical Cancer Research was published in January 1995. [2] By 1 December 1994, 128 manuscripts had been submitted for publication by investigators representing a variety of clinical and laboratory disciplines not only from the United States but also from the international research community. In 1998, the number of manuscripts submitted had risen from 500 in the first year to almost 800. The journal reported an acceptance rate of 52% at that time. With the aim to publish only papers of high quality, the editors decided to increase the stringency of review. [3]

Abstracting and indexing

The journal is abstracted and indexed in Chemical Abstracts, Index Medicus, MEDLINE, Science Citation Index, and Current Contents/Clinical Medicine. According to the Journal Citation Reports , the journal has a 2013 impact factor of 8.193, ranking it 13th out of 202 journals in the category "Oncology". [4]

Related Research Articles

Samuel Ray Denmeade is a Professor of Oncology, Urology and pharmacology and molecular sciences at the Johns Hopkins University School of Medicine. Over 10 of his published papers have each been cited over 100 times.

<span class="mw-page-title-main">Personalized medicine</span> Medical model that tailors medical practices to the individual patient

Personalized medicine, also referred to as precision medicine, is a medical model that separates people into different groups—with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease. The terms personalized medicine, precision medicine, stratified medicine and P4 medicine are used interchangeably to describe this concept, though some authors and organizations differentiate between these expressions based on particular nuances. P4 is short for "predictive, preventive, personalized and participatory".

The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research. Based in Philadelphia, the AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the etiology, prevention, diagnosis, and treatment of cancer. Founded in 1907 by 11 physicians and scientists, the organization now has more than 58,000 members in 142 countries and territories. The mission of the AACR is to prevent and cure cancer through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.

<span class="mw-page-title-main">Targeted therapy</span> Type of therapy

Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells. Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy. However, the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.

<i>British Journal of Cancer</i> Academic journal

The British Journal of Cancer (BJC) is a twice-monthly professional medical journal published by Springer Nature's Nature Research.

<span class="mw-page-title-main">Cancer and Leukemia Group B</span> U.S. research cooperative group

Cancer and Leukemia Group B is a cancer research cooperative group in the United States.

<span class="mw-page-title-main">Gordon McVie</span> British oncologist and cancer researcher (1945–2021)

John Gordon McVie was an international authority on the treatment and research of cancer. He wrote over 350 peer-reviewed articles, editorials and books. McVie was born in Glasgow, Scotland and died of non-Hodgkin lymphona and COVID-19 in Bristol, England.

<i>Clinical Lung Cancer</i> Academic journal

Clinical Lung Cancer is a peer-reviewed medical journal that has been published by Elsevier since 2011. It was established by the CIG Media Group in 1999.

Allied Academies is a reportedly fraudulent corporation chartered under the laws of North Carolina. Its postal address is in London, United Kingdom. It presents itself as an association of scholars, with supporting and encouraging research and the sharing and exchange of knowledge as its stated aims. The organization consists of 30 affiliate academies, which provide awards to academics and publish academic journals both online and in hard copy for members. Since 2015 the organization has been listed on Jeffrey Beall's list of "potential, possible, or probable predatory scholarly open-access publishers". It is in a partnership with OMICS Publishing Group which uses its website and logo. In 2018, OMICS owner Srinubabu Gedela declared that he had informed the Nevada court that Allied Academies was a subsidiary of OMICS International. During a conference in 2018, they falsely listed a prominent chemist among its organizing committee who had not agreed to this and was not affiliated with Allied Academies.

<span class="mw-page-title-main">Tower Cancer Research Foundation</span>

Tower Cancer Research Foundation (TCRF) is a 501(c)(3) non-profit organization dedicated to clinical research, patient support and community education. It was established in 1996 in Beverly Hills, California.

<span class="mw-page-title-main">John Mendelsohn (doctor)</span>

John Mendelsohn was a president of the University of Texas MD Anderson Cancer Center in Houston. He was an internationally recognized leader in cancer research.

<span class="mw-page-title-main">Biomedical sciences</span> Application of science to healthcare

Biomedical sciences are a set of sciences applying portions of natural science or formal science, or both, to develop knowledge, interventions, or technology that are of use in healthcare or public health. Such disciplines as medical microbiology, clinical virology, clinical epidemiology, genetic epidemiology, and biomedical engineering are medical sciences. In explaining physiological mechanisms operating in pathological processes, however, pathophysiology can be regarded as basic science.

Current Gene Therapy is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Liang Cheng. The focus of this journal is pre-clinical or clinical research on gene therapy. Formats of publication include original research reports, review papers, and rapid communications ("letters").

Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Ruiwen Zhang. The journal covers research on contemporary molecular drug targets involved in cancer, including medicinal chemistry, pharmacology, molecular biology, genomics, and biochemistry. Current Cancer Drug Targets publishes original research reports, review papers, and rapid communications ("letters").

<span class="mw-page-title-main">Thomas Hutson</span> American oncologist and cancer researcher

Thomas E. Hutson is an American medical oncologist and cancer researcher based in Dallas, Texas. He is the director of Genitourinary Oncology Program and co-director of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center. He is a Professor of Medicine at the Texas A&M Health Science Center College of Medicine and serves as a chair of Genitourinary Research for US Oncology and McKesson.

<span class="mw-page-title-main">Richard Marais</span> Cancer researcher

Richard Malcolm Marais is Director of the Cancer Research UK (CRUK) Manchester Institute and Professor of Molecular Oncology at the University of Manchester.

Jason S. Lewis is a British radiochemist whose work relates to oncologic therapy and diagnosis. His research focus is a molecular imaging-based program focused on radiopharmaceutical development as well as the study of multimodality small- and biomolecule-based agents and their clinical translation. He has worked on the development of small molecules as well as radiolabeled peptides and antibodies probing the overexpression of receptors and antigens on tumors.

<span class="mw-page-title-main">Andrea Apolo</span> American medical oncologist

Andrea B. Apolo is an American medical oncologist specialized in bladder cancer research. She is an investigator in the National Cancer Institute's genitourinary malignancies branch and head of the bladder cancer section.

References

  1. 1 2 "About Clinical Cancer Research". American Association for Cancer Research. Retrieved 2010-07-16.
  2. Mendelsohn, J (1995). "Inaugural editorial". Clinical Cancer Research. 1 (1): 1.
  3. Mendelsohn, J (1999). "Editorial". Clinical Cancer Research. 5 (1): 1.
  4. "Journals Ranked by Impact: Oncology". 2013 Journal Citation Reports . Web of Science (Science ed.). Thomson Reuters. 2014.